| HOME >> BIOLOGY >> TECHNOLOGY |
76% Of Respondents Under Increasing Pressure To Improve Portfolio Management Efficiency -- Yet 87% Say They Lack Visibility To The Metrics Necessary To Achieve These Gains
Chicago, IL (PRWEB) January 22, 2010 -- ClearTrial (www.cleartrial.com), the leading provider of Clinical Trial Operations (CTO) software, today announced the results of a research study which assesses shifts in the demands on the portfolio management function at biopharmaceutical companies. The first phase of the two-part study that surveyed senior managers in portfolio management, corporate strategy, and clinical operations is available through the ClearTrial website at www.cleartrial.com/research/gap.
The study revealed the existence of a significant "operational gap" between long-range planning and project-level metrics – a gap that hampers informed decision-making. Fully 76% of survey respondents said they are under increasing pressure to improve portfolio management efficiency, yet 87% of those surveyed complained that they lack visibility to key project-level operational metrics for use in long-range planning and for proactively shifting portfolio direction.
Further defining the challenge the industry faces in long-range planning, two years ago only 7% of respondents had to manage to a 5% acceptable variance on their portfolio budget. Today that number has climbed to 33% of respondents, with 67% now needing to stay within 10% of target.
"You can’t fix what you can’t see," observed ClearTrial CEO Mike Soenen in assessing these findings. "How do companies expect to bring portfolio budgets within 5% or 10% variance if they don't have visibility to the activities that drive that variance? This inability to roll up study-level operational forecasts into the portfolio forecast means that companies are not working with current information -- and will only increase the margin of error in long-range planning."
Key findings from the research study support this contention:
|
"Not surprisingly, the majority of those surveyed said that the pressure to improve portfolio efficiencies was increasing, and 90% of them expected that pressure to increase further next year ," added Soenen. "Without the proper processes and systems in place to close this operational gap in portfolio planning, however, the industry will continue to struggle with long-range planning efficiency."
The first part of the research study gathered metrics on the state of current portfolio management practice and challenges. The second phase of the research – scheduled for release in March 2010 – will explore portfolio management best practices that address these challenges.
About ClearTrial®
ClearTrial is the leading provider of Clinical Trial Operations (CTO) software, linking clinical planning, forecasting, and tracking of operational and financial performance in a single, integrated system. ClearTrial’s award-winning software helps life sciences companies streamline their clinical operations from Plan to Payment™ without sacrificing quality of results, providing executives and functional leaders in clinical operations, resource planning, finance, outsourcing, and project management with a common platform that promotes speed, accuracy, and consistency throughout the organization. For more information please visit http://www.cleartrial.com.
ClearTrial® and the ClearTrial logo are registered trademarks owned by ClearTrial, LLC, which may be registered in certain jurisdictions. Any other company or product names mentioned in this release are hereby acknowledged as registered trademarks or trademarks of their respective owners.
For more information contact:
Mike Lange
ClearTrial
+1 630.986.9800 x112
# # #
Read the full story at http://www.prweb.com/releases/2010/01/prweb3492184.htm.
'/>"/>
| Source: PRWeb Copyright©2010 Vocus, Inc. All rights reserved |
Related biology technology :
1. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
2. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
3. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
4. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
5. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
6. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
7. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
8. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
9. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
10. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
11. Suntech to Attend Upcoming Investor Conferences and Industry Events
 |
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |